<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065541</url>
  </required_header>
  <id_info>
    <org_study_id>CC-97489-CP-002</org_study_id>
    <secondary_id>2021-000646-17</secondary_id>
    <nct_id>NCT05065541</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography (PET) Imaging Study to Evaluate Enzyme Availability in the Central Nervous System Before and After CC-97489 Administration in Healthy Participants</brief_title>
  <official_title>A Phase 1, Open-label, Multi-part Positron Emission Tomography (PET) Imaging Study to Evaluate the Biodistribution and Radiation Dosimetry of the Monoacylglycerol Lipase (MGLL) PET Ligand [18F]T-401 and to Evaluate Fatty Acid Amide Hydrolase (FAAH) and MGLL Enzyme Availability in the Central Nervous System Using [11C]MK-3168 and [18F]T-401 PET Ligands Before and After Oral Administration of Single and Multiple Doses of CC-97489 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate enzyme availability in the central nervous system&#xD;
      before and after CC-97489 administration in healthy participants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 24, 2021</start_date>
  <completion_date type="Anticipated">September 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 6, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiation dosimetry calculated from PET-CT images</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Calculated % Injected Dose in brain and other key organs and tissues</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Calculated Standard Uptake Volume in brain and other key organs and tissues</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in SUV in the brain based on PET scans</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in VT in the brain based on PET scans.</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>Up to 28 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to 28 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval</measure>
    <time_frame>Day 21</time_frame>
    <description>PR interval: The time from the onset of the P wave to the start of the QRS complex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in ECG parameters: QRS interval</measure>
    <time_frame>Day 21</time_frame>
    <description>QRS interval: A combination of the Q wave, R wave and S wave, the &quot;QRS complex&quot; represents ventricular depolarization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in ECG parameters: QT interval</measure>
    <time_frame>Day 21</time_frame>
    <description>QT interval: Measured from the beginning of the QRS complex to the end of the T wave.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in ECG parameters: QTcF interval</measure>
    <time_frame>Day 21</time_frame>
    <description>QTcF interval: Corrected QT interval using Fridericia's formula (QTcF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Body temperature</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Blood pressure</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Up to Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests</measure>
    <time_frame>Up to Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Up to Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Time to maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-âˆž)</measure>
    <time_frame>Up to 19 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-97489</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_label>Part 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]T-401</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C]MK-3168</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit: www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a Body Mass Index (BMI) of 18.0 to 33.0 kg/m^2, inclusive. BMI = weight&#xD;
             (kg)/(height [m])^2&#xD;
&#xD;
          -  Must be healthy based on medical history, physical examination (PE), clinical&#xD;
             laboratory test results, vital signs, and 12-lead electrocardiogram (ECG) at screening&#xD;
             and check-in&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has any condition, including the presence of laboratory abnormalities, which places&#xD;
             the subject at unacceptable risk if he/she were to participate in the study&#xD;
&#xD;
          -  Is pregnant or breastfeeding&#xD;
&#xD;
          -  Is part of the study site staff personnel or a family member of the study site staff&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-97489</keyword>
  <keyword>Healthy Adults</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Positron Emission Tomography (PET) Imaging</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

